1065 related articles for article (PubMed ID: 29644490)
1. Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma.
Koshkin VS; Grivas P
Curr Oncol Rep; 2018 Apr; 20(6):48. PubMed ID: 29644490
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
Tripathi A; Plimack ER
Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
[TBL] [Abstract][Full Text] [Related]
3. Update of systemic immunotherapy for advanced urothelial carcinoma.
Gartrell BA; He T; Sharma J; Sonpavde G
Urol Oncol; 2017 Dec; 35(12):678-686. PubMed ID: 29079131
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy Advances in Urothelial Carcinoma.
Jain RK; Snyders T; Nandagopal L; Garje R; Zakharia Y; Gupta S
Curr Treat Options Oncol; 2018 Dec; 19(12):79. PubMed ID: 30554335
[TBL] [Abstract][Full Text] [Related]
5. Three Drugs Approved for Urothelial Carcinoma by FDA.
Cancer Discov; 2017 Jul; 7(7):659-660. PubMed ID: 28546286
[TBL] [Abstract][Full Text] [Related]
6. Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.
Katz H; Wassie E; Alsharedi M
Med Oncol; 2017 Sep; 34(10):170. PubMed ID: 28864844
[TBL] [Abstract][Full Text] [Related]
7. FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy.
Suzman DL; Agrawal S; Ning YM; Maher VE; Fernandes LL; Karuri S; Tang S; Sridhara R; Schroeder J; Goldberg KB; Ibrahim A; McKee AE; Pazdur R; Beaver JA
Oncologist; 2019 Apr; 24(4):563-569. PubMed ID: 30541754
[TBL] [Abstract][Full Text] [Related]
8. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
Rouanne M; Roumiguié M; Houédé N; Masson-Lecomte A; Colin P; Pignot G; Larré S; Xylinas E; Rouprêt M; Neuzillet Y
World J Urol; 2018 Nov; 36(11):1727-1740. PubMed ID: 29855698
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
Farina MS; Lundgren KT; Bellmunt J
Drugs; 2017 Jul; 77(10):1077-1089. PubMed ID: 28493171
[TBL] [Abstract][Full Text] [Related]
10. From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma.
Hussain SA; Birtle A; Crabb S; Huddart R; Small D; Summerhayes M; Jones R; Protheroe A
Eur Urol Oncol; 2018 Dec; 1(6):486-500. PubMed ID: 31158093
[TBL] [Abstract][Full Text] [Related]
11. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.
Bellmunt J; Powles T; Vogelzang NJ
Cancer Treat Rev; 2017 Mar; 54():58-67. PubMed ID: 28214651
[TBL] [Abstract][Full Text] [Related]
12. [Immunotherapy for Bladder Cancer].
Büchler T
Klin Onkol; 2017; 30(Supplementum3):6-9. PubMed ID: 29239187
[TBL] [Abstract][Full Text] [Related]
13. Durvalumab for the treatment of urothelial carcinoma.
Alsharedi M; Srivastava R; Elmsherghi N
Drugs Today (Barc); 2017 Dec; 53(12):647-652. PubMed ID: 29517083
[TBL] [Abstract][Full Text] [Related]
14. Urothelial Carcinoma of the Bladder and the Rise of Immunotherapy.
Chism DD
J Natl Compr Canc Netw; 2017 Oct; 15(10):1277-1284. PubMed ID: 28982752
[TBL] [Abstract][Full Text] [Related]
15. Emerging role of immunotherapy in urothelial carcinoma-Advanced disease.
Zibelman M; Ramamurthy C; Plimack ER
Urol Oncol; 2016 Dec; 34(12):538-547. PubMed ID: 27888981
[TBL] [Abstract][Full Text] [Related]
16. Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development.
Powles T; Necchi A; Rosen G; Hariharan S; Apolo AB
Clin Genitourin Cancer; 2018 Apr; 16(2):117-129. PubMed ID: 29325739
[TBL] [Abstract][Full Text] [Related]
17. The Emerging Role of PD-1/PD-L1-Targeting Immunotherapy in the Treatment of Metastatic Urothelial Carcinoma.
Gwynn ME; DeRemer DL
Ann Pharmacother; 2018 Jan; 52(1):60-68. PubMed ID: 28831813
[TBL] [Abstract][Full Text] [Related]
18. [First-line treatment of metastatic urothelial carcinoma : Update immuno-oncology].
Zacharis A; Grüllich C
Urologe A; 2020 Jul; 59(7):797-803. PubMed ID: 32500171
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease.
Yu SS; Dorff TB; Ballas LK; Sadeghi S; Skinner EC; Quinn DI
Clin Adv Hematol Oncol; 2017 Jun; 15(6):466-477. PubMed ID: 28749907
[TBL] [Abstract][Full Text] [Related]
20. [Immunotherapy in bladder cancer-quo vadis? Update on current trials and developments].
Todenhöfer T; Boegemann M
Urologe A; 2020 Jul; 59(7):810-816. PubMed ID: 32468092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
